Meeting
2022 ASCO Annual Meeting
Phase 3 randomized study of loncastuximab tesirine in combination with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL (LOTIS-5).
Authors
Mehdi Hamadani
BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI
Mehdi Hamadani , Yuliya Linhares , Mitul Gandhi , Michael Chung , Helena Adamis , David Ungar , Carmelo Carlo-Stella , Ed Kingsley , Julien Depaus , Sylvia Snauwaert , Michal Kwiatek , Javier López-Jiménez
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT04384484
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS7591)
DOI
10.1200/JCO.2022.40.16_suppl.TPS7591
Abstract #
TPS7591
Poster Bd #
237a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5.
First Author: Mehdi Hamadani
Poster
2022 ASCO Annual Meeting
Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
First Author: Matthew J. Matasar
Poster
2021 ASCO Annual Meeting
A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
First Author: Mark Hertzberg